Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) EBT (2023 - 2025)

Immunocore Holdings (IMCR) has disclosed EBT for 3 consecutive years, with -$15.8 million as the latest value for Q4 2025.

  • Quarterly EBT rose 36.37% to -$15.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$19.1 million through Dec 2025, up 63.92% year-over-year, with the annual reading at -$19.1 million for FY2025, 63.92% up from the prior year.
  • EBT hit -$15.8 million in Q4 2025 for Immunocore Holdings, down from $304000.0 in the prior quarter.
  • In the past five years, EBT ranged from a high of $6.1 million in Q3 2024 to a low of -$25.6 million in Q4 2023.
  • Historically, EBT has averaged -$11.1 million across 3 years, with a median of -$13.0 million in 2024.
  • Biggest five-year swings in EBT: surged 733.52% in 2024 and later crashed 95.01% in 2025.
  • Year by year, EBT stood at -$25.6 million in 2023, then increased by 3.2% to -$24.8 million in 2024, then skyrocketed by 36.37% to -$15.8 million in 2025.
  • Business Quant data shows EBT for IMCR at -$15.8 million in Q4 2025, $304000.0 in Q3 2025, and -$9.7 million in Q2 2025.